Trial Profile
A phase II, randomised, double blind placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 13 Jun 2016 Planned End Date changed from 1 Jan 2017 to 25 Jul 2016.
- 14 May 2014 New trial record